New hope for rare blood cancer: pacritinib trial opens for patients who need better options
NCT ID NCT06986174
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug pacritinib is safe and effective for adults with Waldenström macroglobulinemia, a rare blood cancer, when previous treatments have stopped working. About 30 participants will receive pacritinib and be monitored for tumor shrinkage and side effects. The goal is to control the disease and improve symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOPROLIFERATIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a tailored exercise and diet plan beat cancer fatigue?
- New drug combo aims to make stem cell transplants safer for blood cancer patients
- New PET scan tracer could spot hidden blood cancers
- New drug duo shows promise for rare blood cancer
- New PET tracer aims to spot hidden cancers without biopsy